Richard Young
Urology · Myrtle Beach, SCNPI 1518948587
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,360 of the $10,624 with a category attached, or 78.7%. It is spread thinly across 57 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,322 and has fallen 66.7% since, to $773 in 2025.
Across 283 payments — averaging $37.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$2K
- Neotract Inc.$1K
- Cipla USA Inc.$907
- Dendreon Pharmaceuticals LLC$860
- Boston Scientific$603
- Antares Pharma, Inc.$445
- plus $5K from 51 others
What the payments were for
- Travel & lodging$2,17921%
- Food & beverage$8,36079%
- Education$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$2,067
- ZEMDRI (PLAZOMICIN)$907
- UroLift System$751
- GENERAL KIDNEY STONE DISEASE$372
- JELMYTO$170
- AquaBeam Robotic System$169
- Consumables & Accessories$156
- Barrigel$146
- PROVENGE$142
- Swiss LithoClast Triology$131
- POSLUMA$121
- Nanoknife$120
- UroCuff$114
How this compares
$10,624 in reported general payments places this provider in the 80th percentile of 196 urology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 90 | $79,697 |
| GemtesaVibegron | 62 | $69,636 |
| OrgovyxRelugolix | 18 | $48,072 |
| Mirabegron ErMirabegron | 17 | $17,280 |
| Tamsulosin Hcl | 620 | $12,199 |
| Potassium Citrate ErPotassium Citrate | 81 | $8,492 |
| Solifenacin Succinate | 124 | $4,919 |
| Estradiol | 71 | $4,671 |
| Finasteride | 282 | $4,577 |
| Testosterone | 18 | $4,088 |
| Testosterone Cypionate | 86 | $3,744 |
| Desmopressin Acetate | 23 | $1,940 |
| Silodosin | 25 | $1,544 |
| Tadalafil | 33 | $1,521 |
| Methenamine Hippurate | 13 | $1,363 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $214 | $117,70980 claims |
| Astellas Pharma US IncMyrbetriq | $184 | $79,69790 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 196 urology providers in South Carolina.
Other urology in Myrtle Beach
- Neal ShoreMyrtle Beach$3.2M
- Abhishek SrivastavaMyrtle Beach$41K
- William BogacheMyrtle Beach$41K
- Robert JansenMyrtle Beach$17K
- David RichMyrtle Beach$14K
- Brian RobertsMyrtle Beach$11K
- Manish PatelElgin$213K
- Sandip PrasadCharleston$177K
- Benjamin DropkinGreenville$65K
- Ian MarshallCharleston$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.